Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging.

A residual mass after treatment of lymphoma is a clinical challenge, because it may represent vital tumor as well as tissue fibrosis. Metabolic imaging by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) offers the advantage of functional tissue characterization that is largely independent of morphologic criteria. We compared 18F-FDG PET to computed tomography (CT) in the posttreatment evaluation of 54 patients with Hodgkin's disease (HD) or intermediate/high-grade non-Hodgkin's lymphoma (NHL). Residual masses on CT were observed in 13 of 19 patients with HD and 11 of 35 patients with NHL. Five of 24 patients with residual masses on CT versus 1 of 30 patients without residual masses presented a positive 18F-FDG PET study. Relapse occurred in all 6 patients (100%) with a positive 18F-FDG PET, 5 of 19 patients (26%) with residual masses on CT but negative 18F-FDG PET, and 3 of 29 patients (10%) with negative CT scan and 18F-FDG PET studies (P </=.0001). We observed a higher relapse and death rate in patients with residual masses at CT compared with patients without residual masses at CT (progression-free survival at 1 year: 62 +/- 10 v 88 +/- 7%, P =. 0045; overall survival at 1 year: 77 +/- 5 v 95 +/- 5%, P =.0038). A positive 18F-FDG PET study was even more consistently associated with poorer survival: compared with patients with a negative 18F-FDG PET study, the 1-year progression-free survival was 0% versus 86% +/- 5% (P <.0001) and the 1-year overall survival was 50% +/- 20% versus 92% +/- 4% (P <.0001). The detection of vital tumor by 18F-FDG PET after the end of treatment has a higher predictive value for relapse than classical CT scan imaging (positive predictive value: 100% v 42%). This could help identify patients requiring intensification immediately after completion of chemotherapy. However, 18F-FDG PET mainly predicts for early progression but cannot exclude the presence of minimal residual disease, possibly leading to a later relapse.

[1]  W. Murphy,et al.  Radiation fibrosis: differentiation from recurrent tumor by MR imaging. , 1985, Radiology.

[2]  I. Magrath,et al.  High frequency of benign mediastinal uptake of gallium-67 after completion of chemotherapy in children with high-grade non-Hodgkin's lymphoma. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  D Front,et al.  Gallium 67 imaging in monitoring lymphoma response to treatment , 1988, Cancer.

[4]  S. Kvaløy,et al.  Magnetic resonance imaging and 67gallium scan in mediastinal malignant lymphoma: a prospective pilot study. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  P. Hoffer,et al.  The role of gallium-67 in the clinical evaluation of cancer. , 1984, Seminars in nuclear medicine.

[6]  A. Wolf,et al.  Metabolic trapping as a principle of oradiopharmaceutical design: some factors resposible for the biodistribution of [18F] 2-deoxy-2-fluoro-D-glucose. , 1978, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[7]  S M Larson,et al.  Validation of gallium-67-citrate single-photon emission computed tomography in biopsy-confirmed residual Hodgkin's disease in the mediastinum. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[8]  C. Zuiani,et al.  Magnetic resonance imaging and 67Ga scan versus computed tomography in the staging and in the monitoring of mediastinal malignant lymphoma: a prospective pilot study. , 1996, Magma.

[9]  F. Gherlinzoni,et al.  Monitoring bulky mediastinal disease with gallium-67, CT-scan and magnetic resonance imaging in Hodgkin's disease and high-grade non-Hodgkin's lymphoma. , 1996, Leukemia & lymphoma.

[10]  T. Hickish,et al.  Role of magnetic resonance imaging in predicting relapse in residual masses after treatment of lymphoma. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  A. Al-Katib,et al.  Lymphomas: MR imaging contrast characteristics with clinical-pathologic correlations. , 1990, Radiology.

[12]  K. Ho,et al.  Diffuse thymic hyperplasia following chemotherapy for nodular sclerosing Hodgkin's disease: An immunologic rebound phenomenon? , 1983, Cancer.

[13]  B. Glimelius,et al.  Residual mediastinal masses in Hodgkin disease: prediction of size with MR imaging. , 1989, Radiology.

[14]  A. Santoro,et al.  Comparison of gallium scan, computed tomography, and magnetic resonance in patients with mediastinal Hodgkin's disease. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  P. Stomper,et al.  Gallium-67 imaging: a predictor of residual tumor viability and clinical outcome in patients with diffuse large-cell lymphoma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  A. Belakhlef,et al.  False-positive FDG-PET imaging of the thymus of a child with Hodgkin's disease. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[17]  G. Canellos,et al.  Residual mass in lymphoma may not be residual disease. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  O. Israel,et al.  The role of Ga-67 scintigraphy in evaluating the results of therapy of lymphoma patients. , 1995, Seminars in nuclear medicine.

[19]  D. Bumann,et al.  Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  R. Hardoff,et al.  Uptake of gallium-67 citrate and [2-3H]deoxyglucose in the tumor model, following chemotherapy and radiotherapy. , 1985, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.